Literature DB >> 32703751

Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Splenic Marginal Zone Lymphoma.

Domenico Albano1, Luca Camoni2, Raffaele Giubbini3, Francesco Bertagna3.   

Abstract

INTRODUCTION: Splenic marginal zone lymphoma (SMZL) is an indolent non-Hodgkin lymphoma usually with a good prognosis, but no clear metabolic behavior at fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). The aim of our analysis was to investigate the prognostic role of baseline 18F-FDG PET/CT parameters in SMZL.
MATERIALS AND METHODS: We retrospectively included 42 patients who received 18F-FDG-PET/CT before any treatments, and PET images were evaluated visually and semi-quantitatively by measuring lesion to liver (L-L) maximum standardized uptake volume (SUVmax) ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume, and total lesion glycolysis. Progression-free (PFS) and overall survival (OS) curves were plotted according to the Kaplan-Meier method.
RESULTS: In all patients, an increased splenic FDG uptake (higher than the background) was identified, showing the presence of diffuse spleen uptake in 35 patients and focal uptake in the remaining 7 patients. At a median follow-up of 51 months, relapse or progression of disease occurred in 23 patients with an average time of 38.1 months from the baseline 18F-FDG PET/CT, and death occurred in 4 patients with an average time of 26.8 months. The estimated 2-year PFS and OS rates were 78% and 90%, respectively, whereas 5-year PFS and OS rates were 63% and 82%, respectively. At multivariate analysis, only L-L SUV R and L-BP SUV R were independent prognostic factors for PFS. In addition, no significant association was discovered for OS, considering all features.
CONCLUSIONS: L-L SUV R and L-BP SUV R were independently correlated with PFS.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MTV; Prognosis; SMZL; Splenic marginal zone lymphoma; TLG

Mesh:

Substances:

Year:  2020        PMID: 32703751     DOI: 10.1016/j.clml.2020.06.018

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  2 in total

1.  What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts.

Authors:  Côme Bommier; Jérôme Lambert; Grzegorz Nowakowski; Emanuele Zucca; Catherine Thieblemont
Journal:  Hemasphere       Date:  2022-01-31

2.  18F-fluorodeoxyglucose positron emission tomography-based prediction for splenectomy in patients with suspected splenic lymphoma.

Authors:  Yingwei Hu; Weiyan Zhou; Siyuan Sun; Yihui Guan; Jiexian Ma; Yanhui Xie
Journal:  Ann Transl Med       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.